iTeos Therapeutics Ownership | Who Owns iTeos Therapeutics?
iTeos Therapeutics Ownership Summary
iTeos Therapeutics is owned by 84.78% institutional investors, 0.70% insiders, and 14.53% retail investors. Blackrock is the largest institutional shareholder, holding 10.41% of ITOS shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.34% of its assets in iTeos Therapeutics shares.
ITOS Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | iTeos Therapeutics | 84.78% | 0.70% | 14.53% |
| Sector | Healthcare Stocks | 49.73% | 8.84% | 41.43% |
| Industry | Biotech Stocks | 47.04% | 8.74% | 44.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock | 3.73M | 10.41% | $55.37M |
| Ra capital management | 3.52M | 9.81% | $52.20M |
| Ecor1 capital | 3.25M | 9.07% | $48.23M |
| Boxer capital | 2.95M | 8.22% | $43.73M |
| Mpm asset management | 2.74M | 7.64% | $40.64M |
| Vanguard group | 2.05M | 5.72% | $30.42M |
| Vestal point capital, lp | 1.75M | 4.88% | $25.97M |
| Bioimpact capital | 1.75M | 4.87% | $25.91M |
| 683 capital management | 1.11M | 3.11% | $16.55M |
| Morgan stanley | 1.09M | 3.04% | $16.17M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Mpm asset management | 2.74M | 22.32% | $40.64M |
| Bioimpact capital | 1.75M | 4.03% | $25.91M |
| Boxer capital | 2.95M | 2.30% | $43.73M |
| Saturn v capital management | 367.43K | 2.06% | $5.45M |
| Vestal point capital, lp | 1.75M | 1.94% | $25.97M |
| Ecor1 capital | 3.25M | 1.48% | $48.23M |
| 683 capital management | 1.11M | 1.25% | $16.55M |
| K2 principal fund | 257.08K | 0.71% | $3.82M |
| Ra capital management | 3.52M | 0.69% | $52.20M |
| Sectoral asset management | 96.97K | 0.58% | $1.44M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Vestal point capital, lp | 1.75M | 1.94% | 1.75M |
| Ecor1 capital | 3.25M | 1.48% | 1.25M |
| Boxer capital | 2.95M | 2.30% | 1.14M |
| Vanguard group | 2.05M | 0.00% | 549.40K |
| Candriam s.c.a. | 509.30K | 0.05% | 509.30K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Braidwell lp | - | - | -1.16M |
| Ra capital management | 3.52M | 0.69% | -900.00K |
| Deerfield management company, l.p. (series c) | - | - | -723.00K |
| Millennium management | 241.31K | 0.00% | -641.68K |
| Morgan stanley | 1.09M | 0.00% | -543.06K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vestal point capital, lp | 1.75M | 1.94% | 1.75M | $25.97M |
| Candriam s.c.a. | 509.30K | 0.05% | 509.30K | $7.56M |
| Clearline capital lp | 156.89K | 0.06% | 156.89K | $2.33M |
| Adar1 capital management | 60.00K | 0.17% | 60.00K | $890.40K |
| Rafferty asset management | 35.98K | 0.00% | 35.98K | $534.02K |
Sold Out
| Holder | Change |
|---|---|
| Nelson, van denburg & campbell wealth management group | -5.00 |
| Avion wealth | -103.00 |
| Pacer advisors | -205.00 |
| Point72 (difc) | -1.23K |
| Metropolitan life insurance co/ny | -1.36K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 | 155 | 11.51% | 36,568,914 | 1.19% | 84 | 0.83% | 83 | 12.16% | 42 | 5.00% |
| Jun 30, 2024 | 138 | 1.47% | 36,138,016 | 4.70% | 100 | 1.09% | 73 | 37.74% | 40 | -25.93% |
| Mar 31, 2024 | 136 | -0.73% | 34,517,358 | -1.12% | 96 | 1.01% | 53 | -29.33% | 54 | 35.00% |
| Dec 31, 2023 | 137 | -8.05% | 34,908,053 | -1.63% | 97 | 0.99% | 75 | 2.74% | 40 | -14.89% |
| Sep 30, 2023 | 149 | 0.68% | 35,487,057 | 2.07% | 99 | 1.05% | 73 | -1.35% | 47 | - |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 855.64K | 2.34% | - |
| iShares Russell 2000 ETF | 671.53K | 1.84% | -1.51K |
| SPDR® S&P Biotech ETF | 549.67K | 1.51% | 6.07K |
| Candriam Eqs L Biotech C USD Cap | 535.59K | 1.47% | - |
| Vanguard Institutional Extnd Mkt Idx Tr | 424.27K | 1.16% | -1.87K |
| BlackRock Advantage Small Cap Core Instl | 423.18K | 1.16% | - |
| Fidelity Small Cap Index | 264.21K | 0.72% | -7.04K |
| iShares Russell 2000 Value ETF | 255.74K | 0.70% | - |
| Belfius Equities Cure C Cap | 233.62K | 0.64% | - |
| Candriam Global Equities Oncology | 233.62K | 0.64% | 148.62K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Nov 19, 2024 | Gall Matthew | Chief Financial Officer | Buy | $38.63K |
| May 10, 2024 | RA CAPITAL MANAGEMENT, L.P. | Former 10% Owner | Buy | $5.71K |
| Oct 12, 2023 | Gall Matthew | Chief Financial Officer | Buy | $41.85K |
| Aug 23, 2023 | Boxer Capital, LLC | - | Sell | $3.71M |
| Aug 23, 2023 | Boxer Capital, LLC | - | Sell | $1.49M |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2024 Q4 | 1 | - |
| 2024 Q3 | - | - |
| 2024 Q2 | 1 | - |
| 2024 Q1 | - | - |
| 2023 Q4 | 1 | - |
ITOS Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools